Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Revenue of Eli Lilly and Company (LLY)
Revenue in 2023 (TTM): $34.12 B
According to Eli Lilly and Company's latest financial reports the company's current revenue (TTM) is $34.12 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Eli Lilly and Company
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $34.12 B | $27.55 B | $12.46 B | $6.55 B | $5.24 B |
| 2022 | $28.54 B | $21.91 B | $9.43 B | $6.81 B | $6.24 B |
| 2021 | $28.32 B | $21.01 B | $8.74 B | $6.16 B | $5.58 B |
| 2020 | $24.54 B | $19.06 B | $7.64 B | $7.23 B | $6.19 B |
| 2019 | $22.32 B | $17.6 B | $6.6 B | $5.27 B | $4.64 B |
| 2018 | $21.49 B | $16.81 B | $9.65 B | $3.68 B | $3.23 B |
| 2017 | $22.87 B | $16.8 B | $7.72 B | $2.2 B | $-204,100,000 |
| 2016 | $21.22 B | $15.57 B | $4.28 B | $3.37 B | $2.74 B |
| 2015 | $19.96 B | $14.92 B | $4.49 B | $2.79 B | $2.41 B |
| 2014 | $19.62 B | $14.68 B | $4 B | $3 B | $2.39 B |
| 2013 | $23.11 B | $18.21 B | $5.23 B | $5.89 B | $4.68 B |
| 2012 | $22.6 B | $17.81 B | $4.51 B | $5.41 B | $4.09 B |
| 2011 | $24.29 B | $19.22 B | $7.18 B | $5.35 B | $4.35 B |
| 2010 | $23.08 B | $18.71 B | $8.15 B | $6.53 B | $5.07 B |
| 2009 | $21.84 B | $17.59 B | $7.74 B | $5.36 B | $4.33 B |
| 2008 | $20.38 B | $16 B | $13.47 B | $-1,307,600,000 | $-2,071,900,000 |
| 2007 | $18.63 B | $14.38 B | $6.77 B | $3.88 B | $2.95 B |
| 2006 | $15.69 B | $12.14 B | $5.75 B | $3.42 B | $2.66 B |
| 2005 | $14.65 B | $11.17 B | $5.2 B | $2.72 B | $1.98 B |
| 2004 | $13.86 B | $10.63 B | $4.92 B | $2.94 B | $1.81 B |
| 2003 | $12.58 B | $9.91 B | $4.23 B | $3.26 B | $2.56 B |
| 2002 | $11.08 B | $8.9 B | $3.61 B | $3.46 B | $2.71 B |
| 2001 | $11.54 B | $9.38 B | $4.22 B | $3.55 B | $2.78 B |
| 2000 | $10.86 B | $8.81 B | $3.51 B | $3.86 B | $3.06 B |
| 1999 | $10 B | $8.34 B | $3.74 B | $3.25 B | $2.72 B |
| 1998 | $9.24 B | $7.71 B | $3.29 B | $2.67 B | $2.1 B |
| 1997 | $8.52 B | $6.66 B | $4.68 B | $510.2 M | $-385,100,000 |
| 1996 | $7.35 B | $5.77 B | $2.32 B | $2.03 B | $1.52 B |
| 1995 | $6.76 B | $5.43 B | $2.47 B | $1.77 B | $2.29 B |
| 1994 | $5.71 B | $4.46 B | $2.32 B | $1.7 B | $1.29 B |
| 1993 | $6.45 B | $4.89 B | $1 B | $701.9 M | $480.2 M |
| 1992 | $6.17 B | $4.64 B | $1.5 B | $1.18 B | $708.7 M |
| 1991 | $5.73 B | $4.37 B | $1.96 B | $1.88 B | $1.31 B |
| 1990 | $5.19 B | $3.92 B | $1.73 B | $1.6 B | $1.13 B |
| 1989 | $4.18 B | $3.15 B | $1.23 B | $1.33 B | $939.5 M |
| 1988 | $4.07 B | $2.94 B | $1.18 B | $1.12 B | $761 M |
| 1987 | $3.64 B | $2.53 B | $779.3 M | $595 M | $643.7 M |
| 1986 | $3.72 B | $2.55 B | $957.9 M | $876.3 M | $558.2 M |
| 1985 | $3.27 B | $2.23 B | $820 M | $796.6 M | $517.6 M |